Catalyst Pharmaceuticals (NASDAQ:CPRX) Stock Price Expected to Rise, Truist Financial Analyst Says

Catalyst Pharmaceuticals (NASDAQ:CPRX) had its price objective lifted by Truist Financial from $30.00 to $36.00 in a report published on Monday morning,Benzinga reports. Truist Financial currently has a buy rating on the biopharmaceutical company’s stock.

A number of other equities analysts also recently commented on CPRX. StockNews.com raised shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, August 9th. Citigroup lifted their price target on shares of Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the company a “buy” rating in a report on Friday, August 9th. Finally, HC Wainwright reiterated a “buy” rating and set a $30.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Friday, November 8th. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Catalyst Pharmaceuticals currently has an average rating of “Buy” and an average target price of $30.50.

Catalyst Pharmaceuticals Stock Down 4.9 %

Shares of NASDAQ CPRX opened at $21.69 on Monday. The stock’s 50 day moving average price is $20.97 and its two-hundred day moving average price is $18.28. Catalyst Pharmaceuticals has a 52-week low of $13.00 and a 52-week high of $24.27. The stock has a market capitalization of $2.59 billion, a P/E ratio of 18.38, a PEG ratio of 3.67 and a beta of 0.75.

Insider Buying and Selling

In other Catalyst Pharmaceuticals news, Director David S. Tierney sold 15,000 shares of Catalyst Pharmaceuticals stock in a transaction on Wednesday, August 21st. The stock was sold at an average price of $20.10, for a total transaction of $301,500.00. Following the sale, the director now owns 348,874 shares of the company’s stock, valued at $7,012,367.40. The trade was a 4.12 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Steve Miller sold 150,000 shares of the stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $20.35, for a total value of $3,052,500.00. Following the completion of the transaction, the insider now directly owns 675,124 shares of the company’s stock, valued at approximately $13,738,773.40. The trade was a 18.18 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 11.00% of the company’s stock.

Institutional Investors Weigh In On Catalyst Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of CPRX. Arizona State Retirement System increased its stake in Catalyst Pharmaceuticals by 2.2% during the 2nd quarter. Arizona State Retirement System now owns 29,733 shares of the biopharmaceutical company’s stock valued at $461,000 after buying an additional 654 shares during the period. GAMMA Investing LLC boosted its holdings in shares of Catalyst Pharmaceuticals by 62.1% in the third quarter. GAMMA Investing LLC now owns 1,778 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 681 shares in the last quarter. Ameritas Investment Partners Inc. increased its stake in shares of Catalyst Pharmaceuticals by 6.9% during the first quarter. Ameritas Investment Partners Inc. now owns 11,116 shares of the biopharmaceutical company’s stock valued at $177,000 after acquiring an additional 720 shares during the period. XTX Topco Ltd raised its holdings in Catalyst Pharmaceuticals by 7.5% during the second quarter. XTX Topco Ltd now owns 11,134 shares of the biopharmaceutical company’s stock worth $172,000 after purchasing an additional 773 shares in the last quarter. Finally, Strategic Advocates LLC raised its holdings in Catalyst Pharmaceuticals by 6.5% during the second quarter. Strategic Advocates LLC now owns 14,142 shares of the biopharmaceutical company’s stock worth $219,000 after purchasing an additional 864 shares in the last quarter. 79.22% of the stock is currently owned by institutional investors.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.